Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedMar 02, 2026
DataAggregated Company Financials
Companies543
  • 7D1.2%
  • 3M7.3%
  • 1Y28.8%
  • YTD7.7%

Over the last 7 days, the Biotech industry has risen 1.2%, and Amgen contributed the most with a gain of 2.3%. Meanwhile, BeOne Medicines actually underperformed within the industry, shrinking 14% in the last week. In the last 12 months, the industry was up 29%. Looking forward, earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 03 Mar 2026US$1.4tUS$169.4b-US$12,634,834,488.1021.8x-106.9x8x
Thu, 29 Jan 2026US$1.3tUS$163.6b-US$15,062,594,674.9119.8x-84.8x7.8x
Sat, 27 Dec 2025US$1.3tUS$163.6b-US$15,776,614,106.3522x-79.3x7.6x
Mon, 24 Nov 2025US$1.2tUS$163.8b-US$16,230,751,145.9818.2x-74.3x7.4x
Wed, 22 Oct 2025US$1.2tUS$163.4b-US$18,378,998,645.5816.2x-64.4x7.2x
Fri, 19 Sep 2025US$1.1tUS$163.5b-US$18,381,106,242.3916.9x-58.1x6.5x
Sun, 17 Aug 2025US$1.1tUS$163.6b-US$18,739,718,949.9515.6x-57.4x6.6x
Tue, 15 Jul 2025US$974.2bUS$155.8b-US$23,412,837,702.4818x-41.6x6.3x
Thu, 12 Jun 2025US$959.4bUS$155.9b-US$23,944,577,514.8416.9x-40.1x6.2x
Sat, 10 May 2025US$879.4bUS$154.9b-US$24,542,496,165.1116.7x-35.8x5.7x
Mon, 07 Apr 2025US$735.9bUS$118.6b-US$37,018,260,571.7320.1x-19.9x6.2x
Wed, 05 Mar 2025US$831.7bUS$119.0b-US$37,123,415,733.9016.4x-22.4x7x
Fri, 31 Jan 2025US$990.2bUS$149.5b-US$26,311,030,486.4317.4x-37.6x6.6x
Sun, 29 Dec 2024US$977.8bUS$149.9b-US$26,372,711,577.3016.2x-37.1x6.5x
Tue, 26 Nov 2024US$1.0tUS$150.0b-US$26,579,608,946.2716.4x-38.2x6.8x
Thu, 24 Oct 2024US$897.0bUS$113.1b-US$36,020,164,121.5521x-24.9x7.9x
Sat, 21 Sep 2024US$927.5bUS$113.2b-US$35,987,032,000.3121.9x-25.8x8.2x
Mon, 19 Aug 2024US$883.2bUS$113.2b-US$35,819,260,655.8322.3x-24.7x7.8x
Wed, 17 Jul 2024US$1.2tUS$164.5b-US$28,050,454,935.0729.4x-42.6x7.3x
Fri, 14 Jun 2024US$1.2tUS$164.5b-US$28,081,541,373.9827.8x-41.3x7.1x
Sun, 12 May 2024US$1.1tUS$164.6b-US$26,967,551,943.9823.3x-41.2x6.7x
Tue, 09 Apr 2024US$1.1tUS$164.4b-US$23,377,181,270.8821x-48.3x6.9x
Thu, 07 Mar 2024US$1.2tUS$167.9b-US$21,278,119,441.9516x-55.9x7.1x
Sat, 03 Feb 2024US$1.4tUS$203.9b-US$24,418,168,728.0019.2x-58.9x7.1x
Mon, 01 Jan 2024US$1.4tUS$204.9b-US$22,199,078,413.0019.8x-62.6x6.8x
Wed, 29 Nov 2023US$1.2tUS$204.8b-US$22,005,071,481.0017.8x-55.6x6x
Fri, 27 Oct 2023US$1.2tUS$207.5b-US$12,993,510,910.0016.8x-93.2x5.8x
Sun, 24 Sep 2023US$1.3tUS$207.5b-US$12,879,333,723.0017.1x-97.9x6.1x
Tue, 22 Aug 2023US$1.3tUS$207.6b-US$12,363,308,148.0017.5x-102.3x6.1x
Thu, 20 Jul 2023US$1.1tUS$186.6b-US$15,972,272,220.0012.8x-71.5x6.1x
Sat, 17 Jun 2023US$1.2tUS$186.3b-US$16,045,332,946.0012.1x-72.3x6.2x
Mon, 15 May 2023US$1.2tUS$191.7b-US$12,222,188,637.0013.8x-94.5x6x
Wed, 12 Apr 2023US$1.2tUS$198.3b-US$3,303,389,351.0013.9x-351.9x5.9x
Fri, 10 Mar 2023US$1.1tUS$199.1b-US$4,987,732,730.0015x-221x5.5x
Price to Earnings Ratio

-221x


Total Market Cap: US$1.1tTotal Earnings: -US$4,987,732,730.00Total Revenue: US$199.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -67.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.7x is lower than the industry's current PS ratio of 8.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 5.2% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.57%
Healthcare1.76%
Biotech1.23%
Biotech1.23%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$388.162.3%
+US$4.7b		24.9%PE27.1x
ABBV AbbVieUS$232.081.1%
+US$4.6b		9.7%PE98x
VRTX Vertex PharmaceuticalsUS$496.833.3%
+US$4.0b		2.8%PE31.9x
UTHR United TherapeuticsUS$503.906.2%
+US$1.7b		62.5%PE16.5x
MRNA ModernaUS$53.576.5%
+US$1.3b		77.0%PS10.9x

Latest News

UTHR
US$503.90
United Therapeutics
7D
6.2%
1Y
62.5%
ABBV
US$232.08
AbbVie
7D
1.1%
1Y
9.7%

AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition

AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.
AMGN
US$388.16
Amgen
7D
2.3%
1Y
24.9%
CAI
US$20.14
Caris Life Sciences
7D
14.2%
1Y
n/a
PVLA
US$135.02
Palvella Therapeutics
7D
53.7%
1Y
590.6%
VRTX
US$496.83
Vertex Pharmaceuticals
7D
3.3%
1Y
2.8%

Vertex Pharmaceuticals (VRTX): The Diversification Juggernaut – Beyond the CF Monopoly

Vertex Pharmaceuticals (VRTX) has entered a transformative era where its identity is shifting from a "Cystic Fibrosis (CF) company" to a multi-disease powerhouse. Following its Q4 fiscal 2025 earnings report on February 12, 2026 , the stock demonstrated resilience, trading at $495.43 as of February 27.
REGN
US$781.67
Regeneron Pharmaceuticals
7D
-0.7%
1Y
14.1%
ONC
US$316.99
BeOne Medicines
7D
-14.5%
1Y
29.1%
INSM
US$149.33
Insmed
7D
-6.1%
1Y
95.7%
GILD
US$148.95
Gilead Sciences
7D
-0.6%
1Y
28.4%
CYTK
US$62.22
Cytokinetics
7D
-8.8%
1Y
45.1%
MRNA
US$53.57
Moderna
7D
6.5%
1Y
77.0%
MNKD
US$3.28
MannKind
7D
-41.1%
1Y
-36.1%

MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case

Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.
BIIB
US$191.82
Biogen
7D
-2.3%
1Y
35.4%

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.
MIRM
US$92.29
Mirum Pharmaceuticals
7D
-12.8%
1Y
100.7%

MIRM: Elevated Expectations Will Hinge On Upcoming PSC Trial Outcome

Analysts have lifted their fair value estimate for Mirum Pharmaceuticals to $95.00 from $56.92, citing higher modeled revenue growth, improved profit margin assumptions, and reinforced confidence in Livmarli and the broader bile acid portfolio, following recent price target increases and new Outperform initiations across the Street. Analyst Commentary Recent Street research around Mirum Pharmaceuticals has centered on the commercial trajectory for Livmarli, the broader bile acid portfolio, and upcoming clinical milestones.
ROIV
US$28.94
Roivant Sciences
7D
4.3%
1Y
184.6%

ROIV: 2026 Clinical Readouts Are Expected To Unlock Further Upside

Roivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.